(Fmoc-Cys-OH)2

Fmoc-Cys-OH)2 is a cysteine-based, Fmoc-protected amino acid building block supplied as a dimeric or bis-unit reagent form, designed for peptide synthesis workflows where cysteine residues are introduced with orthogonality to other side-chain functionalities. The Fmoc group supports standard base-labile deprotection in Fmoc chemistry, while the cysteine functionality enables downstream peptide assembly and, where required, further derivatization of the thiol after chain construction. This reagent format is commonly selected by peptide and medicinal chemistry groups that need reliable cysteine incorporation for native or modified cysteine-containing peptides.

1. Fmoc Peptide Synthesis

Fmoc-Cys-OH)2 is used by custom peptide synthesis teams and medicinal chemistry laboratories to introduce cysteine residues during solid-phase peptide synthesis, leveraging the Fmoc protecting group for controlled N-terminal activation and coupling cycles. The cysteine side chain provides a chemically distinct handle for producing cysteine-containing peptide sequences used in structure-activity relationship studies, disulfide mapping strategies, and peptide motif development. Researchers often choose this reagent when they want cysteine incorporation that aligns with established Fmoc-based workflows and when the cysteine side-chain functionality is intended to be carried through peptide assembly for subsequent processing.

2. Cysteine Side-Chain Derivatization

Fmoc-Cys-OH)2 supports workflows that require post-synthetic modification of cysteine thiol chemistry, including conversion to thiol-reactive derivatives or controlled oxidation to define disulfide patterns in peptide constructs. Chemical biology groups and peptide material developers use cysteine-containing peptides as scaffolds for conjugation chemistry, where the thiol can be transformed into more stable or functional forms after peptide synthesis. This makes the reagent relevant for generating peptide reagents used in protein interaction studies, surface immobilization strategies, or building blocks for functional peptide libraries where cysteine chemistry is a key variable.

3. Peptide Library And SAR Workflows

Fmoc-Cys-OH)2 is frequently employed in peptide library construction and SAR campaigns that include cysteine-bearing analogs, because cysteine often drives conformational effects and enables site-specific chemical diversification. Peptide discovery teams use cysteine-containing sequences to probe structure-function relationships, compare analogs with different cysteine-derived modifications, and generate reference peptides for analytical method development. The Fmoc-protected amino acid format supports reproducible incorporation within parallel synthesis workflows, which is valuable for high-throughput analog generation and downstream characterization by LC-MS and related analytical methods.

4. Protein Engineering Mimic Peptides

Fmoc-Cys-OH)2 is also used to prepare cysteine-containing peptides that mimic protein segments or functional motifs for protein engineering and chemical biology studies. Researchers use these peptide mimics to investigate local chemistry around cysteine residues, evaluate conformational constraints imposed by cysteine-derived linkages, and generate standards for binding or interaction assays that rely on defined thiol/disulfide states. In these contexts, the ability to build cysteine-bearing peptides through Fmoc-based assembly and then manage cysteine side-chain chemistry during or after synthesis makes the reagent a practical choice for motif-focused studies and mechanistic peptide experiments.

1. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

2. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate

5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment